Company intelligence / Profile preview

Protega Pharmaceuticals Inc.

Princeton, New Jersey, United Statesprotegapharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Protega has received FDA approval for ROXYBOND (oxycodone hydrochloride) immediate-release tablets with abuse-deterrent technology for pain management. The company has approval for 5, 10, 15, and 30 milligram doses, with the 10mg dose becoming the most commonly prescribed[4][6][8].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

oxycodone

Commercial

Indications: Severe pain

Beyond the preview

Go deeper on Protega Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protega Pharmaceuticals Inc..

Explore the full profile